| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Praxis Precision Medicines, Inc.$324.99
-8.13 (-2.44%)
C 54Pipeline Score Richly Valued Pharma · Clinical
Market Cap
9.58 B
EPS
-13.38
P/E Ratio
-
Value Trade
184.56 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
77.99 M
Operating CF
-86.15 M
Total Assets
1.46 B
Total Liabilities
50.24 M
Equity
1.41 B
D/E Ratio
12,345
1.71 %
Week
-0.13 %
1 Month
3.32 %
3 Month
110.68 %
6 Month
11.24 %
5 Year
-11.66 %
All Time
Cash Data
Cash Position
786.87 M
Monthly Burn
28.72 M
Runway
25.5 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
398.57 K
52 Week Range
35.21 - 358.76
% held by Insiders
6.41 %
% held by Institutions
109.17 %
Enterprise Value
8.79 B
Total Shares
27.89 M
Short %
14.34 %
Float Shares
27.80 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Praxis Precision Medicines, Inc.
370Total events
7Upcoming
86Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 7
Event history 363
Jul 7, 2026
▲Partnership / LicenseulixacaltamideCorporate
Strategic collaboration with Remagine Labs to develop transdermal ulixacaltamide
essential tremorsource ↗
Jun 29, 2026
●Major Amendment SubmittedPRAX-562Regulatory Filing
Submission of additional sensitivity analyses deemed major amendment by FDA
SCN2A and SCN8A developmental and epileptic encephalopathiessource ↗
Jun 22, 2026
▲Breakthrough Therapy DesignationelsunersenDesignation
FDA grants Breakthrough Therapy Designation for elsunersen
Seizures associated with SCN2A Developmental and Epileptic Encephalopathy caused by Gain of Function variantssource ↗
Jun 22, 2026
▲Topline ReadoutelsunersenClinical Data
Positive topline results from EMBRAVE Part A: 77% sham-adjusted seizure reduction
Seizures associated with SCN2A Developmental and Epileptic Encephalopathy caused by Gain of Function variantssource ↗
Jun 22, 2026
▲Primary Endpoint MetelsunersenClinical Data
Primary endpoint met: 77% sham-adjusted reduction in monthly seizures
Seizures associated with SCN2A Developmental and Epileptic Encephalopathy caused by Gain of Function variantssource ↗
Jun 22, 2026
▲Enrollment CompleteelsunersenTrial
Enrollment completed in EMBRAVE Part A (9 patients)
Seizures associated with SCN2A Developmental and Epileptic Encephalopathy caused by Gain of Function variantssource ↗
Jun 22, 2026
◆Enrollment UpdateelsunersenTrial
EMBRAVE3 pivotal study is enrolling approximately 30 patients
Seizures associated with SCN2A Developmental and Epileptic Encephalopathy caused by Gain of Function variantssource ↗
Jun 1, 2026
▼Primary Endpoint MissedvormatrigineClinical Data
POWER1 study did not meet primary endpoint of percent change in monthly seizure frequency
focal onset seizuressource ↗
Jun 1, 2026
▲Secondary Endpoint DatavormatrigineClinical Data
Secondary endpoint of 50% response rate met; higher dose (30 mg) showed more pronounced seizure reduction in second half
focal onset seizuressource ↗
Jun 1, 2026
▲Safety Data UpdatevormatrigineClinical Data
Vormatrigine generally well-tolerated; AE-related discontinuations <10%
focal onset seizuressource ↗
Jun 1, 2026
▲OLE InitiatedvormatrigineTrial
Approximately 90% of vormatrigine arm patients transitioned to and remain in open label extension
focal onset seizuressource ↗
Drug Pipeline Intelligence
C54
Pipeline Score $1.1B
Pipeline ValueRichly Valued
Valuation Signal9
Drugs Scored0.1x
rNPV / MCap Top 82%
Small Cap (rank 165 of 911)
Percentile RankPraxis Precision Medicines, Inc. carries a moderate pipeline score (54/100), with $1.7B risk-adjusted pipeline value, led by vormatrogine in Epilepsy, Tonic-Clonic (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| vormatrogine Small molecule | Epilepsy, Tonic-Clonic | Phase 3 | NCT07287163 | 44% | $696M | ENROLLING BY_INVITATION | 700 | VERY_FAST | D (25) | Dec 31, 2028 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
vormatrigine | focal onset seizures | Phase 2/3 | 2026-06-02 | 50% response rate; less than 10% adverse event-related discontinuations; approximately 90% of patients transitioned to OLE study Read More | Praxis Precision Medicines Provides Vormatrigine Program Update Read More | |
vormatrigine | focal onset seizures | Phase 2/3 | 2026-06-02 | 50% response rate; less than 10% adverse event-related discontinuations; approximately 90% of patients transitioned to OLE study Read More | Praxis Precision Medicines Provides Vormatrigine Program Update Read More | |
vormatrigine | focal onset seizures | Phase 2/3 | 2026-06-02 | 50% response rate; less than 10% adverse event-related discontinuations; approximately 90% of patients transitioned to OLE study Read More | Praxis Precision Medicines Provides Vormatrigine Program Update Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PRAX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PRAX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PRAX▼ -2.4%today
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
Praxis Precision Medicines and Remagine Labs have announced a strategic collaboration to develop a transdermal delivery system for ulixacaltamide, aimed at treating essential tremor. This partnership seeks to broaden the drug's market reach and enhance its competitive positioning. Praxis has made an equity investment in Remagine, emphasizing their commitment to the collaboration as they prepare for ulixacaltamide's FDA review.
Read more →PRAXPraxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Praxis Precision Medicines announced an extension of the FDA review period for relutrigine, now set for December 27, 2026. The extension follows the submission of additional analyses deemed a major amendment. No new clinical studies were requested, and the company remains confident in its application to address significant unmet needs in SCN2A and SCN8A developmental and epileptic encephalopathies.
Read more →PRAX▲ +7.5%on this news
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
Praxis Precision Medicines has received FDA Breakthrough Therapy Designation for elsunersen, an antisense oligonucleotide aimed at treating seizures linked to SCN2A Developmental and Epileptic Encephalopathy. The designation follows positive results from the EMBRAVE Part A trial, which demonstrated a significant reduction in seizures among treated patients. Elsunersen is now positioned for expedited development, reflecting its potential as a first disease-modifying therapy for this condition.
Read more →PRAX▼ -5.1%on this news
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
Read more →PRAX▲ +8.1%on this newsshared move
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Praxis Precision Medicines, Inc. has granted restricted stock unit awards to thirteen new non-executive employees as part of its 2024 Inducement Plan. This initiative, compliant with Nasdaq Listing Rule 5635(c)(4), aims to attract talent by offering equity awards. The units will vest annually over four years, contingent on continued employment.
Read more →PRAX▼ -23%on this newsshared move
Praxis Precision Medicines Provides Vormatrigine Program Update
Praxis Precision Medicines announced mixed results from the Phase 2/3 POWER1 study of vormatrigine for focal onset seizures. While the primary endpoint was not achieved, the secondary measure showed promise with a 50% response rate and better seizure reduction at higher doses. The company is pausing enrollment in the POWER2 study to evaluate the program further.
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
Read more →PRAXPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2026
Praxis Precision Medicines, Inc. announced the granting of restricted stock unit awards to 21 new non-executive employees as part of its 2024 Inducement Plan. This initiative is designed to attract talent in accordance with Nasdaq Listing Rule 5635(c)(4). The stock units will vest over four years, contingent on continued employment.
Read more →PRAXPraxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
Praxis Precision Medicines will report its Q1 2026 financial results on May 7, 2026, and provide a corporate update. The company will also participate in the Bank of America Securities Health Care Conference on May 12, 2026. The live webcast of both events will be accessible through their website.
Read more →PRAX▲ +8.4%on this news
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
Read more →PRAXPraxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
Praxis Precision Medicines announced the presentation of its Phase 3 Essential3 program results for ulixacaltamide at the AAN 2026 Annual Meeting. This program is notable for being the first positive Phase 3 trial in essential tremor, a condition affecting millions. The company will showcase its findings through multiple presentations and discussions at the event.
Read more →PRAXPraxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Read more →PRAXPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 2, 2026
Praxis Precision Medicines, Inc. announced the granting of restricted stock unit awards to eighteen new non-executive employees as part of its 2024 Inducement Plan. This initiative, in accordance with Nasdaq Listing Rule 5635(c)(4), aims to incentivize new hires. The awards will vest over four years, contingent on continued employment.
Read more →PRAXPraxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Read more →PRAXPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 4, 2026
Praxis Precision Medicines, Inc. announced the granting of restricted stock unit awards to fourteen new non-executive employees under its 2024 Inducement Plan. This initiative is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to the company. The awards will vest over four years, contingent on continued employment.
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Read more →PRAXPraxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
Praxis Precision Medicines will announce its financial results for Q4 and full year 2025 on February 19, 2026. The company will host a conference call and webcast to discuss these results and provide a corporate update. Additionally, Praxis management will attend two upcoming investor conferences, enhancing their visibility in the market.
Read more →PRAXPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 5, 2026
Praxis Precision Medicines, Inc. announced the grant of restricted stock units to eight new non-executive employees under its 2024 Inducement Plan. This initiative aims to attract talent in accordance with Nasdaq Listing Rule 5635(c)(4). The stock units will vest over four years, contingent on continued employment.
Read more →PRAX▲ +6.3%on this news
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
Praxis Precision Medicines has appointed Dr. Orrin Devinsky as Head of Clinical Strategy. Dr. Devinsky, a leading figure in epilepsy research, will guide the company's clinical strategy and medical affairs. His extensive experience and previous contributions to epilepsy therapies will be instrumental as Praxis advances its late-stage portfolio toward commercialization.
Read more →PRAXPraxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
Read more →PRAXPraxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
Praxis Precision Medicines has announced significant leadership changes, including the appointments of Jeffrey B. Kindler and Stuart Arbuckle to its board, and promotions for Megan Sniecinski and Dr. Steven Petrou. These changes aim to position the company for growth as it prepares for commercial launches and late-stage development of its CNS therapies. The new leadership is expected to enhance Praxis's strategic and operational capabilities.
Read more →PRAXPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced the grant of restricted stock unit awards to three new non-executive employees under its 2024 Inducement Plan. This grant, covering 434 shares, is in compliance with Nasdaq Listing Rule 5635(c)(4) aimed at attracting new talent. The stock units will vest in four equal installments, contingent on continued employment, indicating a strategy to retain skilled personnel amidst organizational growth.
Read more →PRAX▲ +7.2%on this newsshared move
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
Read more →PRAXPraxis Precision Medicines, Inc. Announces Proposed Public Offering
Praxis Precision Medicines, Inc. has proposed a public offering of its common stock, including pre-funded warrants for certain investors. The offering is intended to bolster capital for clinical development and is managed by a consortium of reputable financial firms. An additional 30-day option for underwriters to purchase more shares has been included. The company filed the offering under a shelf registration statement with the SEC, which became effective late last year.
Read more →PRAX▲ +13.2%on this news
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
Praxis Precision Medicines has received Breakthrough Therapy Designation from the FDA for ulixacaltamide, a treatment for essential tremor. This designation is based on positive results from the Essential3 Phase 3 program. The company plans to submit a New Drug Application (NDA) in early 2026 following successful pre-NDA meetings with the FDA.
Read more →PRAXPraxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
Praxis Precision Medicines announced that it has successfully completed discussions with the FDA, confirming plans to file a New Drug Application (NDA) for relutrigine in early 2026. The drug, which targets developmental and epileptic encephalopathies, has shown promising results in clinical trials, including significant improvements in seizure control. This marks a significant step towards providing a new treatment option for affected children.
Read more →PRAXPraxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
Praxis Precision Medicines announced a significant development in its EMBRAVE3 trial for elsunersen, an antisense oligonucleotide aimed at treating early-onset SCN2A developmental and epileptic encephalopathy. The FDA has agreed to convert the study into a single-arm, baseline-controlled design, allowing all participants to receive the drug from the start. This change aims to address the high unmet needs of patients while preserving the rigor necessary for regulatory approval. The trial is expected to enroll 30 patients and report topline results in 2026.
Read more →PRAX▲ +9.3%on this newsshared move
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
Praxis Precision Medicines presented promising results for relutrigine and vormatrigine at the American Epilepsy Society Annual Meeting. The EMBOLD study indicated relutrigine's potential as a disease-modifying treatment for SCN2A and SCN8A-DEE, while the RADIANT study showcased vormatrigine's efficacy in seizure reduction. Praxis plans to discuss the New Drug Application with the FDA soon.
Read more →PRAXPraxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Praxis Precision Medicines announced positive results from the EMBOLD study for relutrigine, targeting SCN2A and SCN8A developmental and epileptic encephalopathies. The study was halted early for efficacy based on a recommendation from the Data Monitoring Committee. Praxis plans to present the topline study results at the upcoming American Epilepsy Society Annual Meeting and has an upcoming meeting with the FDA to discuss the next steps for submitting a New Drug Application. Relutrigine has shown improved seizure control and received multiple designations from regulatory agencies.
Read more →PRAXPraxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
Praxis Precision Medicines announced a successful pre-NDA meeting with the FDA regarding ulixacaltamide, aimed at treating essential tremor. The FDA provided positive feedback and alignment on the NDA's content, which is expected to be submitted in early 2026. This development follows the promising results from the Essential3 program, which showed significant improvements in patients' daily functioning. Essential tremor currently has no effective treatment options for many patients, highlighting the importance of ulixacaltamide in addressing this unmet medical need.
Read more →PRAX▲ +12.4%on this news
Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
Praxis Precision Medicines, Inc. will present its latest advancements in epilepsy research at the 2025 American Epilepsy Society Annual Meeting in Atlanta, Georgia. The presentations will focus on the company's precision epilepsy pipeline, highlighting data on various candidates including vormatrigine, relutrigine, and elsunersen. The scientific exhibit will offer interactive sessions to discuss the latest findings and progress in their clinical trials. Praxis aims to showcase its commitment to developing transformative therapies for people living with epilepsy.
Read more →PRAX▼ -13.3%on this newsshared move
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Praxis Precision Medicines, Inc. has announced its participation in an upcoming fireside chat hosted by HCWainwright analyst Doug Tsao. The session will focus on a deep dive into the data related to their therapeutic, Ulixacaltamide, with guest statistician Prof. Chuck McCullogh from UC San Francisco. CEO Marcio Souza will also take part in this informative discussion scheduled for November 24, 2025.
Read more →PRAXPraxis Precision Medicines to Participate in Upcoming Investor Conferences
Praxis Precision Medicines, Inc. announced its participation in upcoming investor conferences. The company focuses on developing therapies for central nervous system disorders by translating genetic insights. Their portfolio includes multiple clinical-stage candidates aimed at addressing neurological disorders. Replays of the earnings webinar and conference webcasts will be available for 90 days post-event.
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Praxis Precision Medicines announced positive results from two pivotal Phase 3 studies for ulixacaltamide in essential tremor, with a pre-NDA meeting with the FDA scheduled for Q4 2025. The company plans to accelerate the development of relutrigine for SCN2A and SCN8A DEE patients following a Type B meeting with the FDA. Additionally, recruitment for the POWER1 study of vormatrigine is complete, with topline results expected in 1H 2026.
Read more →PRAX▼ -5.6%on this newsshared move
Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
Praxis Precision Medicines has announced positive feedback from the FDA regarding the accelerated development of relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies. Following a comprehensive meeting, the FDA agreed that a positive interim analysis from the EMBOLD trial could support a New Drug Application (NDA) submission in early 2026. This development is significant as there are currently no FDA-approved therapies for these conditions.
Read more →PRAX▲ +16.8%on this news
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
Praxis Precision Medicines, Inc. has announced a public offering of 3,025,480 shares at $157.00 per share, aiming to raise approximately $525 million. The offering includes pre-funded warrants and is expected to close around October 20, 2025. Underwriters have a 30-day option for additional shares, with the offering being made under a shelf registration statement.
Read more →PRAX▲ +183.7%on this news· ran to +231% by day 3shared move
Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
Praxis Precision Medicines announced positive topline results from two pivotal Phase 3 studies of ulixacaltamide for essential tremor. Both studies met their primary endpoints, demonstrating significant improvements in patient symptoms and a favorable safety profile. The company has requested a pre-NDA meeting with the FDA, aiming for a potential NDA submission in early 2026.
Read more →PRAX▲ +7.3%on this news· ran to +20% by day 3
PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Praxis Precision Medicines, Inc. over potential violations of federal securities laws and unlawful business practices. This follows Praxis's August 2025 financial report, where they revealed troubling mid-stage study results for the anti-seizure medication vormatrigine. The findings indicated significant adverse events among patients, which led to a substantial drop in the company's stock price. Investors who suffered losses are encouraged to contact the law firm for further assistance.
Read more →PRAXPraxis Precision Medicines to Participate in September Investor Conferences
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) will participate in multiple investor conferences in September 2025. Key events include a corporate presentation at the Baird 2025 Global Healthcare Conference, a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference, and a presentation at the TD Cowen 5th Annual Summit. The company encourages interested investors to request one-on-one meetings during these events. Webcasts of the events will also be available for later viewing on the company's website.
Read more →PRAXPraxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
Praxis Precision Medicines, Inc. will present its latest research at the 36th International Epilepsy Congress in Lisbon, focusing on groundbreaking studies related to focal onset seizures and developmental and epileptic encephalopathies. The company's RADIANT study has shown promising topline results, and additional data from other pivotal studies will be shared. Praxis aims to highlight the advancements made in its precision epilepsy pipeline and engage with the clinical and advocacy communities during the event. Attendees will have opportunities to explore the company's innovative therapies and ask questions about their ongoing trials.
Read more →PRAX▼ -6.5%on this newsshared move
Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm
Praxis Precision Medicines, Inc. is facing an investigation by the Portnoy Law Firm over potential securities fraud, prompting the firm to consider a class action lawsuit for investors who incurred losses. The firm's scrutiny follows the company's recent financial results announcement, which revealed concerning mid-stage clinical trial outcomes for its anti-seizure medication, vormatrigine. After the announcement, Praxis's stock price fell by 5.55%, further fueling investor concerns about the company's financial health and management practices.
Read more →PRAX▼ -5.5%on this newsshared move
Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
Praxis Precision Medicines has announced positive topline results from the Phase 2 RADIANT study of vormatrigine, a treatment for focal onset seizures. Over an 8-week period, participants experienced a median reduction of 56.3% in seizure frequency, with notable results indicating 22% achieved complete seizure control. The drug demonstrated rapid efficacy, with more than half of the patients showing significant response within the first week. Praxis plans to advance clinical trials based on these encouraging findings.
Read more →PRAX▼ -5.5%on this newsshared move
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Read more →PRAXPraxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
Praxis Precision Medicines, Inc. has announced a conference call scheduled for August 4, 2025, to report topline results from its RADIANT trial of vormatrigine and its financial results for the second quarter of 2025. The announcement highlights Praxis's ongoing focus on developing treatments for CNS disorders. Investors can access a live webcast during the event, with a replay available for 90 days on the company's website.
Read more →PRAXPraxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Praxis Precision Medicines, Inc. announced that the U.S. FDA has granted Breakthrough Therapy Designation for relutrigine, intended for treating seizures associated with SCN2A and SCN8A developmental and epileptic encephalopathies. This designation is based on promising results from the Phase 2 EMBOLD trial, where patients experienced significant reductions in seizures. Topline results from the ongoing EMBOLD cohort 2 are expected in the first half of 2026, alongside the initiation of the EMERALD study, which evaluates relutrigine more broadly in developmental epilepsies. This progression underscores the potential of relutrigine in improving treatment outcomes for pediatric patients with severe epilepsy.
Read more →PRAX▲ +6.3%on this news
Praxis Precision Medicines to Participate in Upcoming Conferences
Praxis Precision Medicines to Participate in Upcoming Conferences
Read more →PRAXPraxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
Praxis Precision Medicines recently hosted a virtual investor event to provide updates on its clinical programs focusing on developmental and epileptic encephalopathies. The company highlighted promising data for its lead candidate, relutrigine, which showed a mean seizure reduction of approximately 90% from baseline in initial studies. Praxis also detailed upcoming trials for its antisense oligonucleotide programs targeting specific genetic mutations. The presentations emphasized the substantial market potential for their therapies and outlined their future strategies for development and regulatory approval.
Read more →PRAX▲ +5.7%on this newsshared move
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
Read more →PRAX▼ -9.3%on this news
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
Praxis Precision Medicines is set to host a virtual investor event on May 2, 2025, to discuss its clinical programs for developmental and epileptic encephalopathies. The management will provide insights into ongoing studies, including evaluations of relutrigine and elsunersen for various DEEs. Registration details for the event have been provided, and a replay will be available afterward.
Read more →PRAX▼ -10.3%on this news· ran to -23% by day 3shared move
Praxis Precision Medicines to Participate in Upcoming April Conferences
Praxis Precision Medicines, Inc. has announced its participation in two upcoming investor conferences in April 2025. The company will provide a corporate overview at the Needham Virtual Healthcare Conference and take part in the Piper Sandler Spring Biopharma Symposium. Both events present opportunities for investor engagement, with the availability of one-on-one meetings and replays of the presentations for further reach.
Read more →PRAXPraxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
Praxis Precision Medicines announced plans to present data from four late-stage programs targeting epilepsy and movement disorders at the American Academy of Neurology 2025 Annual Meeting. The meeting will take place from April 5 to 9, 2025, in San Diego, California. Praxis aims to showcase innovations in its pipeline, including updates from its vormatrigine program, and to facilitate discussions with experts in CNS therapies. The company's presentations are expected to provide key insights into their clinical developments.
Read more →PRAX▲ +7.9%on this news
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences
Praxis Precision Medicines, Inc. is set to participate in five upcoming investor conferences. The events include presentations and fireside chats at notable venues in Boston and Miami. Praxis aims to provide investors with insights into its developments in therapies for CNS disorders. Interested investors can request one-on-one meetings with management, and recorded sessions will be available for later viewing on the company's website.
Read more →PRAX▼ -40.6%on this newsshared move
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
Read more →PRAXPraxis Precision Medicines to Present at Two February Investor Conferences
Praxis Precision Medicines to Present at Two February Investor Conferences
Read more →PRAXPraxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
Read more →PRAXDocument Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025 anticipate four c
Praxis Precision Medicines has outlined its 2025 corporate strategy, emphasizing the progress of three late-stage assets with blockbuster potential. The company forecasts pivotal results and NDA filings for ulixacaltamide and relutrigine, with strong interest in ongoing studies. With a financial runway into 2028, Praxis is well-positioned for significant developments in CNS disorder treatments. Key regulatory milestones are anticipated in 2025, including updates from multiple clinical trials that could influence product launches between 2026 and 2028.
Read more →PRAXPraxis Precision Medicines to Present at J.P. Morgan Healthcare Conference
Praxis Precision Medicines, a NASDAQ-listed biopharmaceutical company, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2025. The presentation focuses on their advancements in therapies for CNS disorders. A live webcast of the event will be available, along with a replay for 30 days on their website's Investor section.
Read more →PRAXPraxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
Read more →PRAX▼ -7.4%on this news
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
Read more →PRAX▲ +6.7%on this news
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Read more →PRAXPraxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
Praxis Precision Medicines, Inc. has announced its participation in three investor conferences scheduled for November 2024. Management will engage in discussions at the Truist Securities BioPharma Symposium in New York, the Guggenheim Securities Healthcare Innovation Conference in Boston, and one-on-one meetings at the Jefferies London Healthcare Conference. These events serve as a platform for the company to connect with investors and provide insights into their advancements in therapies for CNS disorders.
Read more →PRAXPraxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
Read more →PRAXPraxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
Praxis Precision Medicines has announced the presentation of its Phase 3 clinical program for ulixacaltamide, aimed at treating essential tremor, at the Movement Disorders Society 2024 International Congress in Philadelphia. The company will feature both a poster and platform presentation during the event. Ulixacaltamide is characterized as a selective inhibitor of T-type calcium channels, intended to reduce abnormal neuronal activities associated with tremors. Following the presentations, additional materials will be available on their website to provide further insights into the program.
Read more →PRAX▲ +9.6%on this newsshared move
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
Praxis Precision Medicines announced plans to present data on its epilepsy portfolio at the International League Against Epilepsy’s 15th European Epilepsy Congress in Rome. The presentations will highlight preclinical and clinical findings from their ongoing epilepsy programs, including promising results from the EMBRAVE and EMBOLD studies. Praxis is also set to initiate its ENERGY program with PRAX-628 this year, further expanding its clinical trials in the epilepsy domain.
Read more →PRAXRELUTRIGINE: EMBOLD Phase 2 Study Topline Results
The Phase 2 EMBOLD study of relutrigine has shown promising results, indicating a 46% reduction in motor seizures among participants when compared to placebo. Notably, 33% of the patients became seizure-free after treatment. The drug was well-tolerated, with only mild to moderate adverse effects reported. However, one severe adverse event of status epilepticus occurred, linked to an infection. The study included a modest sample size, raising some concerns about the broader applicability of the findings.
Read more →PRAXPraxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
Read more →PRAXPraxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Read more →PRAX▼ -5.7%on this news
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
Praxis Precision Medicines, Inc. has announced its plan to report its financial results for the second quarter of 2024 on August 13, 2024. The company is focused on developing therapies for central nervous system disorders. A live webcast will be accessible on the same day, helping to engage investors and provide insights into the company's performance.
Read more →PRAX▼ -7.4%on this news
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
Praxis Precision Medicines has provided a corporate update alongside its Q1 2024 financial results, reporting significant advancements in its clinical programs. The company plans to initiate efficacy studies for PRAX-628 in focal onset seizures starting in late 2024. Additionally, the Essential3 trials for Essential Tremor have shown strong patient recruitment, with results expected later this year. Financially, Praxis has reported a net loss but maintains a solid cash position to support ongoing R&D into 2027.
Read more →PRAXPraxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
Praxis Precision Medicines, a clinical-stage biopharmaceutical company, has announced that it will release its financial results for the first quarter of 2024 on May 13, 2024, prior to the opening of U.S. financial markets. The company specializes in developing therapies for central nervous system disorders linked to neuronal imbalances. This upcoming report may provide insights into the company's financial health and its ongoing research efforts in CNS therapies.
Read more →PRAXPraxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
Read more →PRAXPraxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
Read more →PRAX▲ +23.1%on this newsshared move
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
Praxis Precision Medicines announced positive results from its Phase 2a study of PRAX-628 in epilepsy patients with photoparoxysmal response. The study demonstrated a 100% complete response rate in the 45 mg cohort and an 80% complete response rate in the 15 mg cohort. Safety results were consistent with previous studies, and the company plans to initiate an efficacy study targeting focal onset epilepsy in the second half of 2024. The results enhance the prospects for PRAX-628 as a first-in-class precision sodium channel modulator.
Read more →PRAX▼ -6.3%on this newsshared move
Praxis Precision Medicines to Host PRAX-628 Program Update
Praxis Precision Medicines, Inc. will host a virtual update on March 26, 2024, to discuss its PRAX-628 program for epilepsy. The event will feature insights from Dr. Daniel Friedman, a key opinion leader in the field. PRAX-628 is a promising small molecule that targets sodium-channels in the brain and has shown potential to be a leading treatment option for focal onset epilepsy based on preclinical results. The webcast will be accessible on the company's website for interested parties.
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Read more →PRAX▲ +5.9%on this news· ran to +24% by day 3shared move
Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
Praxis Precision Medicines, Inc. will participate in the TD Cowen 44th Annual Health Care Conference located in Boston from March 4 to 6, 2024. The company's management will engage in investor meetings and take part in a corporate panel discussion titled 'Orphan Epilepsies Corporate Panel Discussion' on March 6 at 10:30 a.m. EST. This event aims to highlight their developments related to CNS disorders. A replay of the webcast will be accessible on the company's website for 90 days afterwards.
Read more →PRAX▲ +11.7%on this news
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
Praxis Precision Medicines, Inc. has announced the pricing of its underwritten public offering, which consists of 3,168,275 shares of common stock priced at $35.50 each, alongside pre-funded warrants for an additional 1,056,725 shares. The total gross proceeds from this offering are expected to be approximately $150 million, set to close on or about January 16, 2024, contingent on market conditions. Activation of this funding is intended to advance the company's research and development initiatives for therapies targeting CNS disorders.
Read more →PRAX▲ +24.9%on this news· ran to +73% by day 3shared move
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
Praxis Precision Medicines provided a promising update on its clinical stage portfolio, highlighting the positive preliminary results from the 15 mg cohort of the PRAX-628 study aimed at epilepsy patients. The company is on track to complete its Phase 3 studies for ulixacaltamide and plans to submit a new drug application by 2025. Additionally, a new licensing agreement with Tenacia Biotechnology is set to extend the drug's reach into the Greater China market. Key topline results from multiple ongoing studies are anticipated throughout 2024.
Read more →PRAX▼ -7.1%on this news· ran to +44% by day 3shared move
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
Praxis Precision Medicines has entered into a licensing and collaboration agreement with Tenacia Biotechnology to develop ulixacaltamide for essential tremor treatment in Greater China. Praxis will receive an upfront payment of $15 million and is eligible for milestone payments totaling up to $264 million, as well as royalties on net sales. This partnership aims to address the significant unmet medical need for effective therapies targeting essential tremor, which affects millions in the region. Ulixacaltamide is designed to inhibit abnormal neuronal activity associated with the disorder.
Read more →PRAX▼ -9.1%on this news
Document UNAUDITED SELECTED FINANCIAL DATA (Amounts in thousands, except share and per share data) Reverse Stock Split On
On November 28, 2023, Praxis Precision Medicines, Inc. executed a 1-for-15 reverse stock split of its common stock. The unaudited financial data highlights significant net losses, with the latest figures showing a net loss of $214,029 for the year ended December 31, 2022. Following the reverse stock split, the net loss per share has risen dramatically, suggesting potential challenges for the company moving forward. This action reflects a strategic response to its financial standing as it continues to report substantial losses across various periods.
Read more →PRAX▼ -9.1%on this news
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
Read more →PRAX▼ -13%on this news
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
Praxis Precision Medicines, a clinical-stage biopharmaceutical company, announced its participation in the Piper Sandler 35th Annual Healthcare Conference. This event is scheduled for November 28, 2023, and will include a live webcast available on the company's website. The conference will allow Praxis to discuss its genetic insights and therapies for central nervous system disorders. A replay of the webcast will be accessible for 90 days post-event.
Read more →PRAXPraxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
Praxis Precision Medicines has received PRIME designation from the European Medicines Agency for its drug elsunersen (PRAX-222) intended for treating SCN2A Gain of Function developmental epilepsies. This designation recognizes the therapeutic potential of elsunersen, which aims to address significant unmet medical needs for patients suffering from SCN2A-DEE. The decision was based on promising data from the EMBRAVE study, highlighting its benefits such as reduced seizures. This positions elsunersen as a potential breakthrough therapy in this field.
Read more →PRAX▲ +6.5%on this news
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Read more →PRAX▲ +5.4%on this news· ran to +17% by day 1shared move
Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
Praxis Precision Medicines, a clinical-stage biopharmaceutical firm, will be part of a panel at the Truist Securities BioPharma Symposium on November 8, 2023. The panel discusses high unmet needs in CNS disorders, reflecting the company's focus on significant healthcare challenges. This event will also be available via live webcast for those unable to attend in person, enhancing its reach and impact.
Read more →PRAXPraxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
Read more →PRAXPraxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
Praxis Precision Medicines, Inc. will host a hybrid R&D Day on October 2, 2023, at 9:00 a.m. EDT, in New York City and virtually. The management team will discuss advancements in their pipeline, including the expected start of a Phase 3 trial for ulixacaltamide in essential tremor and updates on their clinical epilepsy programs. Notable experts in Movement Disorders and Epilepsy will be participating, enriching the event with their insights and perspectives.
Read more →PRAX▲ +5.1%on this news
Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference
Praxis Precision Medicines, Inc. announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference, scheduled for September 12, 2023. The management will engage in a fireside chat to discuss the company's progress and vision. The event aims to provide insights into the company's innovative therapies for CNS disorders, and will be accessible through a live webcast.
Read more →PRAX▲ +5.8%on this news
Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress
Praxis Precision Medicines will present data from two clinical-stage epilepsy programs at the 35th International Epilepsy Congress in Dublin, Ireland from September 2-6, 2023. The data includes findings from the Phase 1 study of PRAX-628 for focal epilepsy, which suggests a potentially best-in-class safety profile. Additionally, findings from the development of PRAX-562 for SCN2A and SCN8A developmental and epileptic encephalopathies will also be highlighted. Both compounds aim to improve the quality of life for patients suffering from epilepsy and have received special designations from the FDA and European Medicines Agency.
Read more →PRAXPraxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
Praxis Precision Medicines has announced its intention to present analyses of patient-focused, clinically meaningful endpoints from its Essential1 study of ulixacaltamide for Essential Tremor at the upcoming MDS International Congress in Copenhagen. CEO Marcio Souza emphasized the significance of their findings, which define a clinically meaningful change for adults with Essential Tremor. The study highlights modified Activities of Daily Living 11 as a key measure of ulixacaltamide's efficacy and durability of effect. This approach aligns with recent FDA guidance on clinical outcome assessments.
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Praxis Precision Medicines announced a positive corporate update and Q2 2023 financial results, indicating the initiation of Phase 3 studies for ulixacaltamide in Q4 2023 following a favorable meeting with the FDA. The company revealed a strong cash position of $124.3 million, providing a financial runway until Q1 2025, while reporting continued progress across its clinical-stage programs. However, they also reported a net loss of $34.3 million for the quarter, emphasizing ongoing financial challenges despite advances in their research pipeline.
Read more →PRAXPraxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
Praxis Precision Medicines has reported positive data regarding ulixacaltamide from the ongoing Essential1 study. Patients treated with ulixacaltamide showed significant improvement in daily living activities over a 14-week period, with no new safety concerns identified. Additionally, a randomized withdrawal sub-study confirmed the robustness of the study design for the anticipated Phase 3 program. This program will further explore the potential benefits of ulixacaltamide in treating Essential Tremor.
Read more →PRAXPraxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
Praxis Precision Medicines announced promising results from the Phase 1 study of PRAX-628, which showed significant pharmacodynamic activity compared to placebo. The trial data included evaluations from a composite quantitative EEG measure, indicating potential as a future treatment for focal onset epilepsy. With the upcoming Phase 2 study expected to report results in the second half of 2023, the company aims to further assess the drug's viability. Positive preclinical data also supports the potential of PRAX-628 as a best-in-class treatment for patients.
Read more →PRAXPraxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
Praxis Precision Medicines, a clinical-stage biopharmaceutical company, will participate in the 2023 Wedbush PacGrow Healthcare Conference on August 9, 2023. The company's management will be on a panel discussing the acceleration and broadened reach of orphan epilepsy development. This involvement emphasizes their focus on therapies for central nervous system disorders, specifically addressing neuronal excitation-inhibition imbalance. Interested parties are encouraged to contact their Wedbush representative for participation details.
Read more →PRAXPraxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
Praxis Precision Medicines announced the successful closing of a public offering, raising net proceeds of $63.3 million, which extends the company's cash runway into Q1 2025. The funds will support various clinical trials, including the enrollment for the Phase 3 study of ulixacaltamide. Additionally, Praxis initiated a Phase 2 study for PRAX-628 aimed at evaluating its effects on photo-sensitive epilepsy patients, with results expected by the end of 2023. The company remains focused on progressing its development pipeline for central nervous system disorders.
Read more →PRAX▲ +18.2%on this newsshared move
Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering
Praxis Precision Medicines, Inc. has priced its public offering at $0.95 per share, intending to raise approximately $59.1 million. The company is offering 55,150,000 shares along with a pre-funded warrant for an additional 7,050,000 shares. The offering, set to close on June 21, 2023, is being managed by Piper Sandler and Truist Securities. Praxis is utilizing a shelf registration statement previously declared effective by the SEC to facilitate this financial move.
Read more →PRAXPraxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
Praxis Precision Medicines has announced plans to initiate its Phase 3 clinical trial for ulixacaltamide, a treatment for essential tremor, after a positive end-of-Phase 2 meeting with the FDA. The trial will consist of a parallel group study and a randomized withdrawal study, with mADL11 as the primary endpoint. The company's strategy aims to capitalize on a new mechanism of action to address the needs of patients with essential tremor, a condition that significantly impacts daily living.
Read more →PRAX▲ +15.2%on this news· ran to +25% by day 1
Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
Praxis Precision Medicines, Inc. announced its upcoming presentation at the 2023 Jefferies Healthcare Conference, scheduled for June 9, 2023. The presentation will focus on the company's efforts in developing therapies for central nervous system disorders. This event will be accessible via live webcast and will also have a replay available for 90 days post-event. The company aims to highlight its innovative approaches to addressing neuronal imbalances in CNS conditions.
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
Ulixacaltamide essential tremor End-of-Phase 2 meeting with FDA scheduled for June 2023 PRAX-628 Phase 1 study results support preclinical profile indicating potential for best-in-class-efficacy for focal epilepsy Cash and investments of $85.8 million as of March 31, 2023 suppo
Read more →PRAXPraxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
PRAX-628 demonstrated a favorable safety and tolerability profile in healthy volunteers at concentrations more than 15-fold the MES EC50; PRAX-628 predicted therapeutic range at least 3-fold wider than current market leader based on MES model Phase 1 results support preclinical
Read more →PRAXPraxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-in
Read more →PRAX▲ +6%on this newsshared move
Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events
BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-in
Read more →PRAXPraxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference
BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-in
Read more →PRAX▼ -65.9%on this news
Praxis Precision Medicines to Present at Upcoming Investor Conferences
BOSTON, March 03, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-in
Read more →PRAX▼ -65.9%on this news
Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
Read more →PRAX▼ -65.9%on this news
Document
Document
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Read more →PRAXPraxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
Read more →PRAXPraxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting
BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inh
Read more →PRAXPraxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies
Praxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies
Read more →PRAX▼ -7.1%on this news
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Read more →PRAXPraxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-in
Read more →PRAX▲ +9.3%on this news
Praxis Precision Medicines Provides Updates on Clinical Stage Pediatric Epilepsy Programs
Praxis Precision Medicines Provides Updates on Clinical Stage Pediatric Epilepsy Programs
Read more →PRAX▲ +9.3%on this news
Praxis Precision Medicines to Present at H.C. Wainwright 24th Annual Global Investment Conference
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-in
Read more →PRAX▲ +19.8%on this newsshared move
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Read more →PRAXPraxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inh
Read more →PRAX▼ -78.1%on this news
Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder
Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder
Read more →PRAX▼ -8.3%on this news· ran to -22% by day 3
Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone
Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone
Read more →PRAX▼ -8.5%on this newsshared move
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results
Read more →PRAX▼ -8.5%on this newsshared move
Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients
Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients
Read more →PRAXPraxis Precision Medicines to Present at BofA Securities 2022 Healthcare Conference
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhi
Read more →PRAX▲ +8.6%on this newsshared move
Praxis Precision Medicines to Provide Corporate Update and Report First Quarter 2022 Financial Results on Monday, May 9, 2022
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhi
Read more →PRAXPraxis Precision Medicines Showcases Largest Targeted Epilepsy Portfolio in Industry at 2022 Epilepsy Day
Praxis Precision Medicines Showcases Largest Targeted Epilepsy Portfolio in Industry at 2022 Epilepsy Day
Read more →PRAXPraxis Precision Medicines to Host Epilepsy Day on April 27, 2022
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-in
Read more →PRAXPraxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting
Praxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting
Read more →PRAX▼ -7.3%on this news
Praxis Precision Medicines to Present at Stifel’s 4th Annual CNS Day
BOSTON, March 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-in
Read more →PRAXPraxis Precision Medicines to Present at Cowen’s 42nd Annual Healthcare Conference
BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-in
Read more →PRAXDocument Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results PRAX-114 Phase 2 3 monotherapy MDD Aria Study topline results expected in June 2022 PRAX-944 P
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results PRAX-114 Phase 2 3 monotherapy MDD Aria Study topline results expected in June 2022 PRAX-944 Phase 2a ET topline results expected in May 2022 to include open-lab
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Read more →PRAXPraxis Precision Medicines to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inh
Read more →PRAXPraxis Precision Medicines Announces Publication of Preclinical Data Highlighting Differentiated and Potent Antiepileptic Activity of PRAX-562
Praxis Precision Medicines Announces Publication of Preclinical Data Highlighting Differentiated and Potent Antiepileptic Activity of PRAX-562
Read more →PRAXPAGE 1 CONFIDENTIAL CORPORATE OVERVIEW JANUARY 2 0 2 2 PAGE 1 PAGE 2 CONFIDENTIAL Forward-looking statements This presentation may contain “forward-looking statements” within the meaning of the Private Secu
Symbols represent mean + SEM, n=6-10 per symbol. Vehicle 0.3 mg/kg 1 mg/kg 3 mg/kg 10 mg/kg Highest dose (120 mg) in human MAD is >6x mouse EC50 at 24h trough PAGE 51 CONFIDENTIAL PRAX-562 development strategy in rare cephalgias and pediatric epilepsies OBJECTIVE Identify PoC and
Read more →PRAXmovementdisor Movement Disorder Day FRIDAY, DECEMBER 17, 2021 2 This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our busine
Movement Disorder Day FRIDAY, DECEMBER 17, 2021 2 This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to ex
Read more →PRAXPraxis Precision Medicines to Host Movement Disorder Day on December 17, 2021
Praxis Precision Medicines to Host Movement Disorder Day on December 17, 2021
Read more →PRAXPraxis Precision Medicines Announces Management Team Appointments
Praxis Precision Medicines Announces Management Team Appointments
Read more →PRAXPraxis Precision Medicines to Present Data from Rare Disease Programs at the American Epilepsy Society 2021 Annual Meeting
Praxis Precision Medicines to Present Data from Rare Disease Programs at the American Epilepsy Society 2021 Annual Meeting
Read more →PRAXPraxis Precision Medicines to Present at Piper Sandler’s 33rd Annual Virtual Healthcare Conference
BOSTON, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, tod
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Read more →PRAXDocument Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results Enrollment on track for 1H22 topline results for PRAX-114 Phase 2 3 monotherapy MDD Aria Study and for PRAX-1
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results Enrollment on track for 1H22 topline results for PRAX-114 Phase 2 3 monotherapy MDD Aria Study and for PRAX-114 Phase 2 dose-ranging MDD Acapella Study PRAX-114 Phase 2 studies
Read more →PRAXPraxis Precision Medicines To Provide Corporate Update And Report Third Quarter 2021 Financial Results On Wednesday, November 3, 2021
BOSTON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, tod
Read more →PRAXPraxis Precision Medicines to Present at Citi's 16th Annual BioPharma Virtual Conference
Praxis Precision Medicines to Present at Citi's 16th Annual BioPharma Virtual Conference
Read more →PRAXPraxis Precision Medicines Reports PRAX-114 Perimenopausal Depression (PMD) Phase 2a Proof-of-Concept Trial Results and Announces Plans to Advance to Phase 2b Study in Women with Menopausal and Mood Symptoms
PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study PRAX-114 was well tolerated in Phase 2a PMD study with no change in overall safety profile CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (N
Read more →PRAXDocument Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enroll
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 topline results in PRAX-114 Phase 2 3 Aria S
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Read more →PRAXPraxis Precision Medicines to Present at 2021 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imba
Read more →PRAXPraxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbal
Read more →PRAXDocument Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer
Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer CAMBRIDGE, Mass., May 25, 2021 - Praxis Precision Medicines, Inc. (NASDAQ PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous
Read more →PRAXPraxis Precision Medicines Prices Public Offering of Common Stock
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbal
Read more →PRAXPraxis Precision Medicines Announces Proposed Public Offering of Common Stock
Praxis Precision Medicines Announces Proposed Public Offering of Common Stock
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results
Read more →PRAXPraxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imb
Read more →PRAXPraxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Cudkowicz
Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Mass., Apr. 29, 2021 Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for
Read more →PRAXPraxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz
Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D. Mass., Apr. 15, 2021 Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the devel
Read more →PRAXPraxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE
CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imb
Read more →PRAXPraxis Precision Medicines to Present at Stifel’s 3rd Annual CNS Day
CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imb
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearanc
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND PRAX-944 Phase 2a high dose cohort topline data expected in mid-ye
Read more →PRAXPraxis Precision Medicines to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 17, 2021
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imb
Read more →PRAXPraxis Precision Medicines Partners With Ciitizen to Improve Patient-Guided Drug Development
Innovative collaboration to be implemented across multiple indications starting with SCN2A-DEE CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the de
Read more →PRAXPraxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations for Severe Pediatric Epilepsy Programs
Praxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations for Severe Pediatric Epilepsy Programs
Read more →PRAXPraxis Precision Medicines Announces CFO Transition
Praxis Precision Medicines Announces CFO Transition CAMBRIDGE, Mass., Dec. 01, 2020 (GLOBAL NEWSWIRE) Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous s
Read more →PRAXPraxis Precision Medicines Provides Update On PRAX-114 IND Submission For The Treatment Of Major Depressive Disorder - Praxis expects to initiate Phase 2/3 clinical trial for PRAX-114 in MDD in 1H21
Praxis Precision Medicines Provides Update On PRAX-114 IND For The Treatment Of Major Depressive Disorder - Praxis expects to initiate Phase 2/3 clinical trial for PRAX-114 in MDD in 1H21- CAMBRIDGE, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) Praxis Precision Medicines, Inc. (NASDA
Read more →PRAXPraxis Precision Medicines Provides Regulatory Update On PRAX-114 Program
Praxis Precision Medicines Provides Regulatory Update On PRAX-114 Program
Read more →PRAXFrom: @fda.hhs.gov Sent: Friday
Sent: Friday, November 6, 2020 2:23 PM @praxismedicines.com> This email is in reference to your IND 145451 dated October 8, 2020 for PRAX-114. This email serves to inform you that we have reviewed your submission and your study has been placed on a full clinical hold. All Hol
Read more →PRAXPraxis Precision Medicines Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance,
Read more →PRAXPraxis Precision Medicines Announces Pricing of Upsized Initial Public Offering
Praxis Precision Medicines Announces Pricing of Upsized Initial Public Offering
Read more →Competitive Position
How PRAX ranks across every disease it competes inCompetitive Position is a premium feature
See how PRAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial